Shawn P Allwein is a notable inventor based in Downingtown, PA (US). He has made significant contributions to the field of pharmaceutical chemistry, holding a total of 8 patents. His work primarily focuses on developing compounds that have therapeutic applications in treating various proliferative disorders.

Latest Patents

Among his latest patents is the invention titled "Fused bicyclic 2,4-diaminopyrimidine derivative as a dual ALK and FAK inhibitor." This invention provides a compound of formula (I) or a salt form thereof, which exhibits ALK and FAK inhibitory activity. It may be utilized in the treatment of proliferative disorders. Another significant patent is "Methods for preparing fused bicyclic 2, 4-diaminopyrimidine derivatives." This disclosure outlines improved methods for preparing specific compounds, including 2-[[5-chloro-2-[[(6S)-6-[4-(2-hydroxyethyl)piperazin-1-yl]-1-methoxy-6,7,8,9-tetrahydro-5Hbenzo[7]annulen-2-yl]amino]pyrimidin-4-yl]amino]-N-methyl-benzamide (CEP-37440).

Career Highlights

Shawn has worked with prominent companies in the pharmaceutical industry, including Cephalon, Inc. and Teva Santé. His experience in these organizations has allowed him to develop innovative solutions and contribute to advancements in drug development.

Collaborations

Throughout his career, Shawn has collaborated with esteemed colleagues, including Laurent D Courvoisier and Martin J Jacobs. These partnerships have fostered a collaborative environment that enhances the innovation process.

Conclusion

Shawn P Allwein is a distinguished inventor whose work in pharmaceutical chemistry has led to significant advancements in the treatment of proliferative disorders. His contributions through patents and collaborations highlight his commitment to innovation in the field.

This text is generated by artificial intelligence and may not be accurate.